tradingkey.logo
tradingkey.logo
Suchen

Nautilus Biotechnology Inc

NAUT
Zur Watchlist hinzufügen
1.730USD
-0.110-5.98%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
218.79MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Nautilus Biotechnology Inc Unternehmen

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

Nautilus Biotechnology Inc Informationen

BörsenkürzelNAUT
Name des UnternehmensNautilus Biotechnology Inc
IPO-datumAug 07, 2020
CEOPatel (Sujal)
Anzahl der mitarbeiter155
WertpapierartOrdinary Share
GeschäftsjahresendeAug 07
Addresse2701 Eastlake Ave East
StadtSEATTLE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl98102
Telefon12063332001
Websitehttps://www.nautilus.bio/
BörsenkürzelNAUT
IPO-datumAug 07, 2020
CEOPatel (Sujal)

Führungskräfte von Nautilus Biotechnology Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Ms. Anna Mowry
Ms. Anna Mowry
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
85.50K
+11.70%
Mr. Kentaro (Ken) Suzuki
Mr. Kentaro (Ken) Suzuki
Chief Marketing Officer
Chief Marketing Officer
4.00K
--
Mr. Sujal Patel
Mr. Sujal Patel
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
--
--
Mr. Matthew S. (Matt) Mcilwain
Mr. Matthew S. (Matt) Mcilwain
Independent Director
Independent Director
--
--
Mr. Matthew L. Posard
Mr. Matthew L. Posard
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Karen Akinsanya
Ms. Karen Akinsanya
Independent Director
Independent Director
--
--
Mr. Nick Nelson
Mr. Nick Nelson
Chief Business Officer, Senior Vice President - Business Development
Chief Business Officer, Senior Vice President - Business Development
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Ms. Anna Mowry
Ms. Anna Mowry
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
85.50K
+11.70%
Mr. Kentaro (Ken) Suzuki
Mr. Kentaro (Ken) Suzuki
Chief Marketing Officer
Chief Marketing Officer
4.00K
--
Mr. Sujal Patel
Mr. Sujal Patel
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Nautilus Biotechnology Inc?

Die fünf größten Anteilseigner von Nautilus Biotechnology Inc sind: Dr. Parag Mallick

Wie viele Institutionen halten Anteile an Nautilus Biotechnology Inc (NAUT)?

Mit Stand vom 2026Q1 halten 180 Institutionen Anteile an Nautilus Biotechnology Inc, mit einem Gesamtmarktwert von etwa 60.30M, was 47.66% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 1539418.00 gestiegen.